New research presented at the European Cardiovascular Society (ESC) Congress 2023 suggests that neratinib, a tyrosine kinase inhibitor typically used in cancer treatment, may hold therapeutic potential for atherosclerosis – a leading cause of cardiovascular disease. The study, conducted on preclinical models, demonstrates that neratinib effectively targets vascular inflammation, a key driver in the development and progression of the disease.
Atherosclerosis, characterized by the buildup of plaques within artery walls, is a chronic inflammatory condition. While statins remain the cornerstone of treatment, they don’t fully address the inflammatory component, leaving a significant unmet medical need. Researchers have been exploring alternative therapies to specifically target inflammation and stabilize plaques, reducing the risk of heart attacks and strokes.
The investigation focused on the role of vascular smooth muscle cells (VSMCs) in atherosclerosis. These cells, when inflamed, contribute to plaque instability and the potential for rupture. Neratinib was found to inhibit the activity of specific tyrosine kinases within VSMCs, thereby dampening the inflammatory response. This inhibition led to a reduction in inflammatory markers and a stabilization of atherosclerotic plaques in the animal models used.
Mechanism of Action
Neratinib’s effectiveness stems from its ability to block signaling pathways involved in inflammation. Specifically, it targets kinases like EGFR and HER2, which are known to play a role in VSMC activation and inflammatory cytokine production. By interrupting these signals, neratinib effectively calms the inflammatory cascade within the artery walls.
The study utilized both in vitro and in vivo models to assess neratinib’s impact. In vitro experiments confirmed the drug’s ability to suppress inflammatory responses in cultured VSMCs. In vivo studies, using models of atherosclerosis, showed that neratinib administration resulted in smaller, more stable plaques, and a reduced inflammatory burden within the arteries.
Researchers emphasize that these findings are preliminary and derived from preclinical studies. Further investigation is crucial to determine if neratinib can translate into a safe and effective treatment for atherosclerosis in humans. Clinical trials are needed to assess the drug’s efficacy, optimal dosage, and potential side effects in a patient population.
However, the results are encouraging, offering a potential new avenue for tackling this widespread and often fatal disease. The repurposing of existing drugs, like neratinib, for cardiovascular applications is gaining traction as a faster and more cost-effective approach to developing novel therapies. This strategy leverages the known safety profile of the drug, potentially accelerating the path to clinical use.
The team plans to continue exploring the mechanisms underlying neratinib’s protective effects and to investigate its potential in combination with existing treatments like statins. The ultimate goal is to develop a comprehensive therapeutic strategy that addresses both the lipid and inflammatory components of atherosclerosis, leading to improved cardiovascular outcomes.
Image Source: Google | Image Credit: Respective Owner
